Evaluation of nephrotoxicity associated with once-daily administration of aminoglycoside

Journal of Pharmacy Technology

Volumn 13, Issue 6, 1997, Pages 258-262

  Nodoushani, Mojgan ^a   Nicolau, David P ^b   Hitt, Catherine M ^b   Quintiliani, Richard ^b   Nightingale, Charles H ^b  

^a HARTFORD HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; BUMETANIDE; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHOLINE SALICYLATE; CONTRAST MEDIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GENTAMICIN; IBUPROFEN; LOOP DIURETIC AGENT; MAGNESIUM SILICATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; TOBRAMYCIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; COMORBIDITY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; MALE; NEPHROTOXICITY; PLEURA EFFUSION; PNEUMONIA; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 0030722248     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512259701300613     Document Type: Article

References (12)

1. Davis BD. Mechanism of the bactericidal action of the aminoglycosides. Microbiol Rev 1987;51:341-50.
2. Begg EJ, Peddie BA, Chambers ST, Boswell DR. Comparison of gentamicin dosing regimens using an in-vitio model. J Antimicrob Chemother 1992;29:427-33.
3. Nordstrom L, Ringberg H, Cronberg S, Tjernstrom O. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990;25:159-73.
4. de Vries PJ, Verkooyen RP, Leguit P, Verbrugh HA. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis 1990;9:161-8.
5. ter Braak EW, de Vries PJ, Bouter KP, van der Vegt SG, Dorrestein GC, Nortier JW, et al. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy for serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990;89:58-66.
6. Sturm AW. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis 1989;159:931-7.
7. Beaucaire G, Leroy O, Beuscart C, Karp P, Chidiac C, Caillaux M. Clinical and bacteriological efficacy and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother 1991;27(suppl):C91-103.
8. Bennett WN, Plamp CE, Gilbert DN, Parker RA, Porter GA. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 1979;140:576-80.
9. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991;35:399-405.
10. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995;39:650-5.
11. Nicolau DP, Belliveau PP, Nightingale CH, Quintiliani R, Freeman CD. Implementation of a once-daily aminoglycoside program in a large community-teaching hospital. Hosp Pharm 1995;30:674-6, 679-80.
12. Bertino JS, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993;167:173-9.